Table 1.
Adverse Event | 100 mg n (%) | 250 mg n (%) | 500 mg n (%) | 1,000 mg n (%) | 1,500 mg n (%) | 2,000 mg n (%) |
---|---|---|---|---|---|---|
Total | 0 (0) | 2 (66.6) | 1 (33.3) | 3 (50.0) | 2 (66.6) | 6 (66.6) |
Fatigue* | 0 (0) | 1 (33.3) | 0 (0) | 1 (16.6) | 1 (33.3) | 0 (0) |
GI Symptoms† | 0 (0) | 0 (0) | 1 (33.3) | 1 (16.6) | 2 (66.6) | 4 (44.4) |
Headache | 0 (0) | 1 (33.3) | 0 (0) | 1 (16.6) | 1 (33.3) | 1 (11.1) |
Other‡ | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (33.3) | 1 (11.1) |
Fatigue includes: Difficulty Concentrating
GI Symptoms include: Eructation, Heartburn, and Indigestion
Other includes: Decreased Heart Rate and Burning with Urination
National Cancer Institute, Common Toxicity Criteria v.2.0